Contraceptive Technology Update – January 1, 2019
January 1, 2019
View Issues
-
With Reclassification and New Name, Doors May Open for Internal Condom
The Food and Drug Administration has reclassified the female condom from a Class III device to a Class II device, putting it in the same category as the male condom.
-
FDA Move Widens Approved Use of Human Papillomavirus Vaccine
The Food and Drug Administration has approved the use of the nine-valent human papillomavirus (HPV) vaccine in women and men ages 27-45. The Advisory Committee on Immunization Practices (ACIP) is scheduled to review further information at its February 2019 meeting, with a potential vote at that time. Insurance reimbursement often is based on ACIP guidance.
-
Researchers Release Initial Results on Developmental Vaginal Ring
In an effort to provide both HIV/AIDS and unintended pregnancy protection, researchers have developed a vaginal ring containing the antiretroviral drug dapivirine and the contraceptive hormone levonorgestrel. Scientists have just released results of an initial clinical trial, noting no safety issues.
-
Research Strides May Offer Keys to Battling Gonorrhea
Researchers are investigating a rapid test that not only checks for gonorrhea infection, but also signals if a particular strain is antibiotic-resistant. On another front, scientists report that one dose of a developmental oral antibiotic proves effective in treating uncomplicated genital infections caused by gonorrhea.
-
Injectable Implant Focus of HIV Treatment/ Prevention Research
Researchers with the University of North Carolina at Chapel Hill and the Centers for Disease Control and Prevention are examining a new drug delivery system that uses dolutegravir, an established HIV drug, in a potential longacting treatment and prevention system. The system has been tested in animal models.
-
Elections Bring Renewed Challenges for Reproductive Rights
The November 2018 elections shook up both Washington, DC, and the political landscape for sexual and reproductive health and rights.